Venclexta, Venclyxto (venetoclax) is a small molecule pharmaceutical. Venetoclax was first approved as Venclexta on 2016-04-11. It is used to treat lymphoid leukemia and myeloid leukemia acute in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia. The pharmaceutical is active against apoptosis regulator Bcl-2. In addition, it is known to target bcl-2-like protein 1, bcl-2-like protein 2, and induced myeloid leukemia cell differentiation protein Mcl-1. Venclexta's patents are valid until 2033-09-06 (FDA).
|Indication||b-cell chronic lymphocytic leukemia, lymphoid leukemia, myeloid leukemia acute|
|Drug Class||Bcl-2 (B-cell lymphoma 2) inhibitors|